Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy

European Heart Journal

Volumn 30, Issue 16, 2009, Pages 2003-2010

  Leonardi, Sergio ^a   Raineri, Claudia ^a   De Ferrari, Gaetano M ^a   Ghio, Stefano ^a   Scelsi, Laura ^a   Pasotti, Michele ^a   Tagliani, Marilena ^a   Valentini, Adele ^a   Dore, Roberto ^a   Raisaro, Arturo ^a   Arbustini, Eloisa ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Cardiovascular magnetic resonance; Hypertrophic cardiomyopathy; Sudden cardiac death; Ventricular tachycardia fibrillation

Indexed keywords

GADOLINIUM PENTETATE; MITOCHONDRIAL DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIAC MAGNETIC RESONANCE; CHILD; COHORT ANALYSIS; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DNA SEQUENCE; ELECTROCARDIOGRAM; FEMALE; GENE MUTATION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE WALL; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGING SYSTEM; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SUDDEN DEATH; THICKNESS; UNIVARIATE ANALYSIS;

ADULT; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; FEMALE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TACHYCARDIA, VENTRICULAR;

EID: 68949131233     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp152     Document Type: Article

References (24)

1. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH III, Spirito P, Ten Cate FJ, Wigle ED. ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003;24:1965-1991.
2. Maron BJ. Sudden death in young athletes. N Engl J Med 2003;349:1064-1075.
3. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 1982;65:1388-1394.
4. Spirito P, Bellone P. Natural history of hypertrophic cardiomyopathy. Br Heart J 1994;72:S10-S12.
5. DeRose JJ Jr, Banas JS Jr, Winters SL. Current perspectives on sudden cardiac death in hypertrophic cardiomyopathy. Prog Cardiovasc Dis 1994;36: 475-484.
6. Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NA, Spirito P, Casey SA, Stanton MS, Betocchi S. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-373.
7. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomiopathy. J Am Coll Cardiol 1999;33:1596- 1601.
8. Maron BJ, Estes NA, Maron MS, Almquist AK, Link MS, Udelson JE. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomiopathy. Circulation 2003;107:2872-2875.
9. Canedo MI, Frank MJ. Therapy of hypertrophic cardiomyopathy: medical or surgical ? clinical and pathophysiologic considerations. Am J Cardiol 1981;48: 383-388.
10. Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR, Kutalek SP, Friedman PL, Bubien RS, Page RL, Powell J. Quality of life in the Antiarrhythmics versus Implantable Defibrillators trial: impact of therapy and influences of adverse symptoms and defibrillator shocks. Circulation 2002;105:589-594.
11. Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, Weil J, Zenovich AG, Maron BJ. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005;112:855-861.
12. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Eur Heart J 2006;27:2099-2140.
13. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995;48:1503-1510.
14. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith JC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003;41:1561- 1567.
15. Larson MG. Analysis of variance. Circulation 2008;117:115- 121.
16. LaValley MP. Logistic regression. Circulation 2008;117: 2395-2399.
17. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
18. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson M, Lesser JR, Hanna CA. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement in cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51:1369-1374.
19. Moon JC, Mogensen J, Elliott PM, Smith JC, Elkington AG, Prasad SK, Pennell DJ, McKenna WJ. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutation in troponin I. Heart 2005;91:1036-1040.
20. Maron BJ, Maron MS, Lesser JR, Hauser RG, Haas TS, Harrigan CJ, Appelbaum E, Main ML, Roberts WC. Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. Am J Cardiol 2008;101: 544-577.
21. Marin-Garcia J, Ananthakrishnan R, Goldenthal MJ, Filiano JJ, Perez-Atayde A. Cardiac mitochondrial dysfunction and DNA depletion in children with hypertrophic cardiomyopathy. J Inherit Metab Dis 1997;20:674-680.
22. Prasad GN, Vanniarajan A, Emmanuel C, Cherian KM, Singh L, Thangaraj K. Novel mitochondrial DNA mutations in a rare variety of hypertrophic cardiomyopathy. Int J Cardiol 2006;109:432-433.
23. Castro MG, Huerta C, Reguero JR, Soto MI, Doménech E, Alvarez V, Gómez-Zaera M, Nunes V, González P, Corao A, Coto E. Mitochondrial DNA haplogroups in Spanish patients with hypertrophic cardiomyopathy. Int J Cardiol 2006;112:202-206.
24. Bondarenko O, Beek AM, Hofman MB, Kuhl HP, Twisk JW, van Dockum WG, Visser CA, van Rossum AC. Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson 2005;7:481-485.